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Abstract
Plasma cell neoplasms are usually associated with normal or decreased platelet count. The
association of thrombocytosis and multiple myeloma is exceedingly rare, with only six such
cases reported in the literature until now. Differentiating clonal from secondary causes of
thrombocytosis can be extremely difficult, yet the distinction has important therapeutic
implications. We report the case of a woman presenting with thrombocytosis that led to the
diagnosis of multiple myeloma. The possible etiological link between both these entities is also
discussed.
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Introduction
Thrombocytosis can be reactive (more common) or a primary myeloproliferative disorder
(MPD) which includes essential thrombocythemia. Many inflammatory (celiac disease,
inflammatory bowel disease, pancreatitis, iron deficiency), rheumatologic (vasculitis),
infectious, or neoplastic conditions cause reactive thrombocytosis. It has been reported with
many solid tumors (e.g., lung, stomach, ovarian and renal cancers) as well [1]. Patients with
secondary thrombocytosis typically have clinically apparent, coexisting, underlying systemic
diseases that account for the elevated platelet count. Unlike patients with secondary
thrombocytosis, those with clonal thrombocytosis have thrombotic, vascular, and bleeding
complications. Hematological malignancies are usually associated with thrombocytopenia. The
association between multiple myeloma and thrombocytosis is infrequent. As far as
thrombocytosis is concerned, the appearance of multiple myeloma has been reported in only
six instances [2]. We report the case of a woman who had multiple myeloma with associated
thrombocytosis. We also reviewed the published data on this association.
Case Presentation
A 32-year-old female presented with complaints of fatigue and tingling sensation in
extremities. Physical exam was unremarkable without evidence of lymphadenopathy or
hepatosplenomegaly. Laboratory findings were significant for hemoglobin (Hb) at 17.2 g/dL,
white blood cell (WBC) count at 9 x 103/µL, and platelets 594x 103/µL. She had no fever, weight
loss, joint pains or other systemic symptoms. Work up for thrombocytosis was initiated. Bone
marrow biopsy showed mildly hypo-cellular marrow (40%) with normal trilineage
hematopoiesis, no evidence of malignancy. Janus kinase 2 (JAK2) exon 12 mutation was
negative. One month later, she presented to the emergency department (ER) with left-hand
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weakness and numbness. Computed tomography (CT) scan showed bilateral cervical chain
lymphadenopathy and 6 x 4.5 cm soft tissue mass in the paraspinal muscle of the thoracic inlet
invading the T1 and posterior rib with pathologic compression fracture (Figure 1).
FIGURE 1: Computed tomography (CT) scan showing A)
cervical lymphadenopathy B) 6 x 4.5 cm mass in the para-
spinal muscle of the thoracic inlet invading the T1 and
posterior part of the first rib with a pathologic compression
fracture
Open biopsy with cervical thoracic fixation from C4-T5 was done. Pathology showed neoplastic
infiltration by lambda restricted monoclonal plasma cells. Flow cytometry of the tumor showed
3% lambda restricted plasma cells (Figure 2).
FIGURE 2: Tissue staining from the open biopsy of the
paraspinal mass
A) hematoxylin eosinophilin stain showing tumor infiltration B) CD 138 positive immunochemical
staining for plasma cells C) staining for lambda restricted plasma cells.
A complete skeletal survey was negative for lytic lesions. Serum protein electrophoresis showed
immunoglobulin (Ig) G lambda restricted M spike of 0.2 g/dL. Lactate dehydrogenase (LDH) was
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normal. Beta-microglobulin level was 2.7 mg/L. Positron emission tomography (PET) scan
showed lytic lesions in her iliac bones and sacrum. A diagnosis of multiple myeloma was made
and Revlimid/Velcade/Dexamethasone (RVD) regimen was given. Following treatment, her
platelet count became normal at 275 x 103/µL. She had a repeat bone marrow biopsy and it was
again normal with negative calreticulin (CALR) gene mutation, negative fluorescence in situ
hybridization (FISH) for myeloma and MPDs and normal cytogenetics. JAK 2 mutation analysis
was positive. The patient does not have any primary bone marrow fibrosis. She went on to have
an autologous stem cell transplant and is currently on maintenance Revlimid therapy.
Discussion
Thrombocytosis is typically discovered as an incidental laboratory finding during routine
workup. However, when found, it creates an important diagnostic challenge. In a study
involving 280 hospitalized patients with platelet counts of one million per cubic millimeter or
higher, 82% (231 patients) had secondary thrombocytosis, 14% (38 patients) had an MPD while
only 4% (11 patients) had thrombocytosis of uncertain cause [3]. In another study including 732
patients with platelet counts of 500,000 per cubic millimeter or higher, 88% (643 patients) had
secondary thrombocytosis; the most frequent underlying causes in these patients were tissue
damage during major surgery, chronic inflammation, infection and carcinoma [4].
Thrombocytosis can be a paraneoplastic manifestation of malignancy. Myeloma has been
reported in cases of MPDs causing thrombocytosis. POEMS syndrome (polyneuropathy,
organomegaly, endocrinopathy, monoclonal protein, and skin changes) can be associated with
thrombocytosis. In the absence of underlying MPD or POEMS syndrome, myeloma is usually
associated with normal or low platelet counts [5-6]. It has been suggested that the cytokine
interleukin-6 (IL-6), an important component in the pathogenesis and progression of multiple
myeloma may provide a common link between multiple myeloma and thrombocytosis. IL-6 is a
potent human myeloma-cell growth factor as well as a promoter of megakaryocytopoiesis [7-8].
However, the exact mechanism still remains unclear; other pathogenetic mechanisms need to
be explored. The association of multiple myeloma, a lymphoproliferative neoplasm, with
thrombocytosis, though documented, is extremely rare [9]. To date, only six cases of myeloma
associated with thrombocytosis have been reported [5-6,10] (Table 1).
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Patient Sex Bone Marrow Biopsy Protein(g/100ml)
Type of M component
in serum
Platelet Count
(/µL) Ref.
1 Male 60% plasma cells Elevated N.R 800,000 [6]
6 Male 6% plasma cells with otherwisenormal marrow 4.99 IgG-Gamma 400-780,000 [6]
3 Male 90% plasma cells 6.2 N.R 400-871,000 [6]
4 Male 65%-70% plasma cells Elevated IgD 931-984,000 [5]
5 Male 10% plasma cells 2.25 IgA-Kappa 980-1420,000 [10]
6 Female 30%-40% plasma cells N.R IgG-Kappa 1220,000 [10]
TABLE 1: Report of cases of multiple myeloma associated with thrombocytosis
g: gram; Ig: immunoglobulin; ml: milliliter; µL: microliter; N.R: not reported; Ref: references.
The challenge of correctly identifying the etiology of thrombocytosis in a patient becomes
crucial when the clinician has to decide treatment options. It is critical to identify the etiology
of thrombocytosis even when it is clinically inapparent so that treatment can be directed to the
underlying disorder [1]. Work up for thrombocytosis should exclude autoimmune disorders,
chronic inflammatory disorders, infections, and iron deficiency. In the absence of MPD,
underlying malignancy should always be ruled out in patients found to have unexplained
thrombocytosis. Although not yet clinically applicable, development of clonality assays and
tests for c-Mpl expression in megakaryocytes and platelets promises to provide diagnostic tools
to differentiate clonal from secondary causes of thrombocytosis [1,11].
Conclusions
Patients with multiple myeloma usually present with thrombocytopenia. However,
thrombocytosis can be an initial presentation. Before ascribing thrombocytosis to a clonal
cause (myeloproliferative disorder), which is a diagnosis of exclusion and has different
therapeutic implications, secondary causes of thrombocytosis must be ruled out.
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